Tirzepatide vs Ozempic Cost: What You'll Actually Pay

Ozempic (semaglutide) generally costs less per month than tirzepatide at list price — about $997 versus roughly $1,060 to $1,080 — but tirzepatide often costs less per pound lost, because it produces greater average weight loss in clinical trials. What you actually pay comes down to your insurance plan, your dose, and whether you use a manufacturer savings card or a cash-pay pharmacy program.

Both drugs are brand-name only in the United States, and neither has a generic version. That single fact explains most of the price gap you see at the pharmacy counter.

Monthly Cost at a Glance

List prices are the published "sticker" prices before insurance, rebates, or coupons. Few people pay them, but they set the baseline for every comparison.

Prices change often, sometimes within a single quarter, so confirm current numbers with the manufacturer or your pharmacy before you budget. Many people who search for tirzepatide vs ozempic price are really asking one question: what will the bill be every month?

Does Tirzepatide Cost More Than Ozempic?

Yes. At list price, tirzepatide runs roughly 6% to 8% higher per month than Ozempic in the United States.

That gap shrinks or disappears once coverage kicks in. Insured patients on either drug often pay a flat copay between $25 and $150, which makes the two nearly identical at the register. The cost of ozempic per month only becomes the deciding factor when you pay cash, carry a high-deductible plan, or your insurer excludes weight-loss treatment.

Brand-name GLP-1 pens usually cost the same no matter the dose, so moving from 0.25 mg to 2 mg of Ozempic does not raise your price. Tirzepatide works the same way through most pharmacies.

Why Tirzepatide and Ozempic Are Priced Differently

• No generics exist. Both molecules are still under patent protection in the US, so there is no low-cost copy to force prices down.
• The FDA approvals differ. Ozempic is approved for type 2 diabetes, and Wegovy is the weight-loss version of semaglutide. Mounjaro targets type 2 diabetes, while Zepbound targets weight management. Insurance rules follow those labels closely.
• Rebates are confidential. Pharmacy benefit managers negotiate undisclosed rebates, so the net price a health plan pays is usually far below the list price patients see online.
• Demand outstripped supply for years. Both drugs spent long stretches on the FDA shortage list, which kept prices firm and opened the door to compounded copies.

Compounded Versions and the Cost Trap

Compounded semaglutide and tirzepatide once sold for $150 to $400 per month, which made them look like the obvious budget answer. After the FDA resolved the shortages in late 2024 and early 2025, large-scale compounding of these molecules became legally restricted.

Some telehealth sellers still market vials labeled for "research use only," but purity, potency, and sterility are not guaranteed. A cheap vial with inconsistent dosing can cost far more in side effects or wasted months than a covered prescription.

Cost Per Pound Lost: Which Is the Better Value?

Monthly price alone can be misleading. Trial data suggest tirzepatide produces greater average weight loss than semaglutide, so the more expensive drug can actually be the cheaper one per pound.

These numbers come from separate trials — STEP-1 and SURMOUNT-1 — with different designs and patient populations. No large head-to-head trial has been completed, so treat the comparison as directional rather than definitive.

If weight loss is your goal, the semaglutide vs tirzepatide weight loss difference matters more than the price difference for most patients. If blood sugar control is the goal, Ozempic and Mounjaro are both approved for type 2 diabetes and are usually covered on similar terms.

Newer Drugs and What They Mean for Price

Retatrutide, cagrilintide, and other next-generation compounds are still in mid- to late-stage trials. None has a published US list price yet, so comparisons like retatrutide vs tirzepatide: which is better cannot be settled on cost grounds today.

More competition tends to push prices down. Oral GLP-1 pills expected in the next few years may pressure brand pricing further, though no one can promise a specific timeline.

How to Lower Your Monthly Cost

1. Check your formulary first. Confirm whether your plan lists Ozempic, Mounjaro, Wegovy, or Zepbound as preferred, and whether prior authorization is required.
2. Use the manufacturer savings card. Eli Lilly and Novo Nordisk both offer copay cards that can bring commercially insured copays down to $25 or so per month.
3. Ask about direct-to-consumer vials. Zepbound single-dose vials and the NovoCare cash-pay program are often the cheapest option for people with no coverage.
4. Appeal a denial in writing. A letter from your prescriber documenting medical need resolves a meaningful share of coverage rejections.
5. Consider a clinical trial. Trial participants typically receive the medication at no cost, though eligibility rules are strict.

Medicare does not cover drugs prescribed solely for weight loss, and that rule shapes pricing decisions for millions of patients.

Whatever you choose, talk with a healthcare professional before starting, stopping, or switching a GLP-1 medication. Fast dose changes can worsen side effects such as nausea, vomiting, and gallbladder problems.